Follow this link to a listing of SEER SINQ's that have been finalized during the month of October 2022. This replaces the previously released NB-2022-020 to correct Q/A 20220025 as it was erroneously listed as 20210025 below. The document has it listed under the correct number.
Highlights of this listing include:
20220034 advises how to properly code multiple treatments for lymphoma cases.
20220032 informs whether micropapillary serous borderline tumor of the testis is reportable.
20220025 clarifies that AIN II is reportable for 2021 as there has been some confusion about reportability.
